Dasatinib ( DrugBank: Dasatinib )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
85	Idiopathic interstitial pneumonia	1

51. Scleroderma

---

Clinical trials : 525 /  Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00764309 (ClinicalTrials.gov)	January 2009	1/10/2008	Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis	An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis	Scleroderma	Drug: dasatinib	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	47	Phase 1/Phase 2	United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02874989 (ClinicalTrials.gov)	December 16, 2016	17/8/2016	Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial	Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Drug: Dasatinib + Quercetin;Drug: Placebo	Wake Forest University Health Sciences	Mayo Clinic;The University of Texas Health Science Center at San Antonio	Completed	50 Years	N/A	All	26	Phase 1	United States